Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus

Part of paid clinical trials in Worcester, Massachusetts.

Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Study ID
NCT05048238
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Tofacitinib — DRUG
    10 participants with Cutaneous lupus erythematosus (CLE). Consenting individuals meeting all entry criteria will undergo 25 days of treatment with tofacitinib (11 mg orally (PO) daily) with evaluation of UVB-mediated cutaneous apoptosis

Study Details

This is a single-arm, multi-site, proof-of-concept study that will evaluate the treatment of 10 participants with cutaneous lupus erythematosus (CLE) with Tofacitinib.

Key Dates

Start date
Sep 30, 2022
Status verified
Aug 2025
Primary completion
Feb 15, 2024
Completion
Feb 29, 2024

Study Design

Enrollment
7 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Tofacinitib
    10 participants receiving 11 mg of Tofacitinib administered orally and daily, from Day 2 to Day 26

Primary Outcome Measure

Change in Percentage of UVB-induced Apoptotic Epidermal Cells [ Time Frame: Day 1 (pre-treatment) to Day 26 ]

Locations (2)

FacilityCityStateZIPSite coordinators
University of Massachusetts Medical SchoolWorcesterMassachusetts01605-
University of Michigan Health System: Department of Internal Medicine, Division of RheumatologyAnn ArborMichigan48109-

Related coverage on Hipa.ai

Find similar trials in Worcester, MA

By condition
Lupus (SLE)
By specialty
RheumatologyAutoimmune disease
By research site
University of Massachusetts Medical School· Worcester, MAUniversity of Michigan Health System: Department of Internal Medicine, Division of Rheumatology· Ann Arbor, MI

Related Studies